Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Residual Tissue Repositories Suitable for MS-Based Proteomics

By LabMedica International staff writers
Posted on 12 Sep 2018
Mass spectrometry-based proteomics has become a powerful tool for the identification and quantification of proteins from a wide variety of biological specimens.

The majority of studies utilizing tissue samples have been carried out on prospectively collected fresh frozen or optimal cutting temperature (OCT) embedded specimens. More...
However, such specimens are often difficult to obtain, in limited in supply, and clinical information and outcomes on patients are inherently delayed as compared to banked samples.

Scientists from the Pacific Northwest National Laboratory (Richland, WA, USA) and their colleagues analyzed 60 patient samples taken from the NCI's Surveillance, Epidemiology, and End Results (SEER) residual tissue repositories, which contain samples from more than 100,000 cancer patients, along with detailed demographic information, data on tumor characteristics, treatment, survival, and cause of death. The 60 samples ranged in their time of storage from seven to 32 years.

The team used 10-plex tandem mass tag (TMT) labeling and divided each sample into six fractions, each of which they then ran on a 100-minute nanoLC gradient upfront of analysis on a Q-Exactive Plus instrument. For phosphopeptide analysis, they used Immobilized Metal Affinity Chromatography (IMAC) enrichment. They found that all 60 samples provided sufficient material for proteome-wide protein expression analysis and 18 of the 60 samples provided enough material for phosphopeptide work.

The investigators identified and quantified a total of 8,582 proteins and 8,073 phosphopeptides across the SEER sample set, indicating that FFPE tissue is amenable to mass spec proteomics analysis. Protein identifications were reduced compared to the identifications possible in comparable optimal cutting temperature (OCT) compound-embedded specimens. Compared to OCT samples, peptide, protein, and phosphopeptide identifications were reduced by 50%, 20%, and 76%, respectively.

Karin D, Rodland, PhD, an expert in mass spectrometry and a senior author of the study, said, “There have been commercial kits available for 12 to 15 years for extracting proteins out of FFPE blocks, and on the face of it, the yields of protein from the FFPE blocks is not that bad. But with the mass spec technologies of 12 to 15 years ago, the rate of identification was very low. You just didn't get good [proteome] coverage out of FFPE blocks. And the assumption was that the formalin crosslinking was causing you to lose identifications. However, improvements in mass spec technology have provided instruments with higher sensitivity and better resolution that are capable of working with smaller amounts of sample.” The study was published on August 3, 2018, in the journal Clinical Proteomics.

Related Links:
Pacific Northwest National Laboratory


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.